Huntington’s Disease (HD) is a neurodegenerative disorder that gives rise to progressive neuronal dysfunction and cell death, that affects muscle coordination and leads to cognitive decline.
The PADDINGTON project supports the development of a series of pharmacodynamic markers to explore potential disease-modifying properties of a potential new drug for Huntington’s Disease treatment, ultimately striving to use the compound to delay disability. > More
European Seventh Framework Programme Project
The aim of the PADDINGTON
project is to develop and ascertain clinical feasibility of a range of pharmacodynamic markers
for the clinical development of SEN0014196, a novel and selective Siena Biotech compound with disease-modifying potential in Huntington’s Disease
. SEN0014196 enjoys Orphan Status
in the EU and in the US and is currently in Phase II clinical development.
News and Events
2012 UK Site Investigators’ Meeting, 30 April-1 May, 2012, The Studio, Birmingham (UK)
As per the World Health Organization (WHO) regulations, Siena Biotech SpA (Partner 1) has received approval for the name “selisistat” as the official International Nonproprietary Name (INN) to designate the SEN0014196 compound. Huntington's disease: A treatment in sight?
New biomarkers will follow disease progress and rapidly detect effects of a novel drug.> More
WP1: PADDINGTON Clinical Study
A multi-centre, double-blind, placebo-controlled, ascending multiple oral dose, sequential group study conducted at two dose levels of SEN0014196 across six EU sites. > More
WP2: Imaging Clinical Study
A multi-centre study across four sites in the EU to expand MRI technique as a biomarker for SEN0014196 clinical studies. > More